[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359366-105":59,"doc-detail-359366-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prdm1-malignant-cells-mediate-an-immunosuppressive-landscape-and-resistance-to-neoadjuvant-chemoradiotherapy-and-immunotherapy-in-esophageal-squamous-cell-carcinoma-research-article","PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma - Research Article","","The mechanisms underlying resistance to neoadjuvant immunotherapy and chemoradiotherapy (nICRT) in locally advanced esophageal squamous cell carcinoma (ESCC) remain poorly understood. A single-arm phase II trial (n=22) with 44.4-month median follow-up showed major pathologic response (MPR) associated with improved 3-year event-free survival and overall survival, contrasted with frequent recurrence in non-major pathological response. Single-cell RNA/TCR sequencing and functional validation identified a PRDM1+ malignant subcluster enriched in non-responders, exhibiting lipid-peroxidation features linked to CTSB and MFSD12 activation and increased ferroptosis susceptibility. These cells promote immune evasion by recruiting immunosuppressive Tregs via IL1A–IL1R2 and activating lipid-metabolizing TREM2+ macrophages through CD47–SIRPA, while MPR patients displayed expanded cytotoxic T-effector clones. PRDM1 is implicated in nICRT resistance, suggesting ferroptosis targeting or disruption of PRDM1+ immune suppression as a strategy for ESCC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prdm1-malignant-cells-mediate-an-immunosuppressive-landscape-and-resistance-to-neoadjuvant-chemoradiotherapy-and-immunotherapy-in-esophageal-squamous-cell-carcinoma-research-article/359366/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prdm1-malignant-cells-mediate-an-immunosuppressive-landscape-and-resistance-to-neoadjuvant-chemoradiotherapy-and-immunotherapy-in-esophageal-squamous-cell-carcinoma-research-article/359366.png","ImageObject",300,407,{"name":92,"@type":93},"Jacob","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What did the phase II trial show about major pathologic response (MPR) versus non-MPR patients?","Question",{"text":112,"@type":113},"MPR patients had superior 3-year event-free survival and overall survival, with no recurrence, while non-MPR patients showed a high recurrence rate.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which cellular subcluster was linked to treatment resistance?",{"text":117,"@type":113},"A PRDM1+ malignant cell subcluster was enriched in non-MPR patients and associated with nICRT resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"How do PRDM1+ malignant cells contribute to an immunosuppressive tumor microenvironment?",{"text":121,"@type":113},"They show lipid-peroxidation characteristics, recruit immunosuppressive regulatory T cells via IL1A–IL1R2 interactions, and activate lipid-metabolizing TREM2+ macrophages via CD47–SIRPA signaling, promoting immune evasion.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},359366,1790729977,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Advanced Science    \n[www.advancedscience.com](www.advancedscience.com)  \n RESEARCH ARTICLE   \nPRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma  \nDijian Shen1   Rui Li2, 3  Yong She4  Xuefei Liu5   Yuanyang Huang2, 3  Yongling Ji6  Keying Chen7  Zhengbo Song8  Runzhe Chen2, 3  Xuan Li2, 3  Qi Zhao4  Qixun Chen1  Ming Chen2, 3   \n1 Department of Thoracic Oncology Surgery, Hangzhou Institute of Medicine, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, Zhejiang, China  2 Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China  3United Laboratory of Frontier Radiotherapy Technology of Sun Yat-Sen University and Chinese Academy of Sciences Ion Medical Technology Co., Ltd., Guangzhou, Guangdong, China  4 Department of Experimental Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China  5 Department of Biochemistry, School of Medicine, Shenzhen Children’s Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, China  6 Department of Radiation Oncology, Hangzhou Institute of Medicine, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, Zhejiang, China  7 Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, America  8 Department of Phase I Clinical Trial, Hangzhou Institute of Medicine, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, Zhejiang, China  \nCorrespondence: Xuan Li ([lixuan@sysucc.org.cn](lixuan@sysucc.org.cn))  Qi Zhao (zhaoqi@sysucc.org.cn)  Qixun Chen (chenqx@zjcc.org.cn)  Ming Chen ([chenming@sysucc.org.cn](chenming@sysucc.org.cn))  \nReceived: 8 August 2025  Revised: 6 January 2026  \nKeywords: Esophageal squamous cell carcinoma (ESCC) | Immune suppression | Lipid peroxidation | neoadjuvant immunotherapy and chemoradiotherapy (nICRT) | PRDM1 | Therapeutic resistance  \nABSTRACT  \nThe mechanisms underlying resistance to neoadjuvant immunotherapy and chemoradiotherapy (nICRT) in locally advanced esophageal squamous cell carcinoma (ESCC) remain poorly understood. Through a single-arm phase II trial (n = 22) with 44.4-month median follow-up, we observed a significant survival disparity: patients achieving major pathologic response (MPR) exhibited superior 3-year event-free survival (EFS) and overall survival (OS), with no recurrence in MPR patients versus 71.4% recurrence in non-major pathological response (NMPR) patients (HR = 17.69, 95% CI 2.25–139.20, p = 0.0063). Integrating singlecell RNA/TCR sequencing and functional validation, we identified a PRDM1+ malignant cell subcluster enriched in NMPR patients and associated with treatment resistance. These cells exhibit strong lipid peroxidation characteristics, a state linked to the transcriptional activation of CTSB and MFSD12 mediated by PRDM1 . This state renders the PRDM1+ malignant cell cluster more susceptible to ferroptosis induction. PRDM1+ cells further recruited immunosuppressive regulatory T cells (Tregs) through IL1A-IL1R2 interactions and activated lipid-metabolizing TREM2+ macrophages via CD47-SIRPA signaling, fostering an immuneevasive microenvironment. Conversely, MPR patients displayed expanded cytotoxic T-effector clones with enhanced tumor-killing capacity. Our findings identify PRDM1 as a key factor associated with nICRT resistance and suggest that targeting ferroptosis  \n\n| Dijian Shen, Rui Li, Yong She, Xuefei Liu, Yuanyang Huang, and Yongling Ji contributed equally to this work.\u003Cbr>|\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, prov","cbCaig4jlkldrJQY","https://ap.wps.com/l/cbCaig4jlkldrJQY","pdf",11374913,21,"English","# Introduction\n## Rationale for studying nICRT resistance in ESCC\n## Role of immunotherapy and immune checkpoint blockade","[{\"question\":\"What did the phase II trial show about major pathologic response (MPR) versus non-MPR patients?\",\"answer\":\"MPR patients had superior 3-year event-free survival and overall survival, with no recurrence, while non-MPR patients showed a high recurrence rate.\"},{\"question\":\"Which cellular subcluster was linked to treatment resistance?\",\"answer\":\"A PRDM1+ malignant cell subcluster was enriched in non-MPR patients and associated with nICRT resistance.\"},{\"question\":\"How do PRDM1+ malignant cells contribute to an immunosuppressive tumor microenvironment?\",\"answer\":\"They show lipid-peroxidation characteristics, recruit immunosuppressive regulatory T cells via IL1A–IL1R2 interactions, and activate lipid-metabolizing TREM2+ macrophages via CD47–SIRPA signaling, promoting immune evasion.\"}]","PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma - Research Article | PDF",1790136761,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5badeda2b1fd15d2886a21465646b095.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b8367e4713177b370d945139a659bf9.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cfd2bebb20fd5b982feddbdcd5b538e5.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/361661e19511c278691effb4bb36e597.webp",980,1287]